Writing in JAMA, four former governmental officials warn that the Trump administration’s involvement in delaying the approval ...

Retail investor chatter around vaccine makers Novavax, Moderna, and Pfizer rose on Wednesday, ahead of a closely watched CDC ...

Peter Marks, who headed the FDA’s Center for Biologics Evaluation and Research before being forced to resign in March, said the agency’s new risk-based COVID-19 vaccine framework contradicts the ...

The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...

Javelin Biotech appointed Dr. Robin Robinson to its board, reinforcing human-centric drug discovery aligned with the FDA ...

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 and older.

The U.S. FDA approved 14 drugs in May, a decline from 20 in April and 22 in March. That brings the year-to-date total for 2025 to 84 approvals, the second highest on record for this period, just ...

A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy ...

FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.

Novavax's COVID-19-influenza vaccines show strong immune response in older adults, paving the way for regulatory approval.

Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 2:00 PM ETCompany ParticipantsJames Patrick Kelly ...